Bimeda acquires Texas Vet Lab
Texas Vet Lab specializes in bovine vaccine research and production as well as operating an on-site laboratory.
Bimeda announced Dec. 11 the acquisition of Texas Vet Lab Inc. (TVL).
Established in 1977 and located in San Angelo, Texas, TVL specializes in bovine vaccine research and production, with a broad range of live and inactivated vaccines to protect against cattle respiratory diseases, Bimeda said.
Bimeda chief executive officer Gavin Tierney said, "The acquisition of Texas Vet Lab marks an important step for Bimeda into the arena of preventative medicine. Following on from the integration of TVL, Bimeda is able to offer our customers a broad suite of both preventative and curative treatment options, including vaccines, antimicrobials, anti-parasitics, hormones and anti-inflammatories.
"TVL also boasts an on-site laboratory, which provides diagnostics for antibiotic sensitivity, as well as virus and bacteria isolation and identification. This will allow us to provide customers with a diagnostics-led approach to the treatment of their animals; ensuring maximum efficacy and rapid recovery from disease," Tierney added.
The U.S. cattle vaccine market has demonstrated strong annual growth over the past five years, Bimeda noted, and this trend is set to continue in line with the global movement toward preventative medicine and a more targeted use of antibiotics.
Against this backdrop, the acquisition will serve as an important tool for Bimeda's long-term growth strategy in the U.S., the company said.
Dave Cunningham, Bimeda chief commercial officer for North America, said, "Texas Vet Lab is an exciting acquisition for Bimeda. With decades of experience in developing innovative vaccines, the TVL team brings a commitment to quality, innovation and serving the customer which perfectly aligns with Bimeda's own values. We see significant long-term growth potential for the business, and with our substantial planned investments in (research and development), sales and marketing, we will drive growth for both the existing vaccine portfolio and new product offerings."
With half a century's experience in the manufacture, distribution and marketing of veterinary pharmaceuticals and animal health products, Bimeda has a well-established global presence in the vet-pharma industry. Since its founding in Ireland in the mid-1960s, the company's growth has helped it achieve a global footprint that now stretches across 75 countries. The Bimeda U.S. head office is in Oakbrook Terrace, Ill.
TAGS: Business